You are here: Industry Insights > Sanofi

News List

Sanofi’s Aubagio obtains EC approval for paediatric multiple sclerosis pharmaceutical-technology
June 22, 2021
Sanofi has obtained approval from the European Commission (EC) for its Aubagio (teriflunomide) to treat paediatric patients aged ten to 17 years with relapsing-remitting multiple sclerosis (RRMS).
Sanofi Invests $425M in Flu Vaccine Manufacturing Facility contractpharma
June 18, 2021
Newly licensed U.S. manufacturing facility to increase availability of Fluzone High-Dose Quadrivalent.
CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms firstwordpharma
June 18, 2021
CytoReason today announced the initiation of a project with French global biopharmaceutical company Sanofi, which will utilize its cell-centered models and deconvolution techniques to suggest mechanistic insights for each asthma endotype.
Sanofi partners with BIG, EORTC, AFT to study amcenestrant for ER+ breast cancer treatment expresspharma
June 07, 2021
Amcenestrant is an oral SERD that antagonises and degrades the estrogen receptor (ER), resulting in inhibition of the ER signaling pathway.
Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the US americanpharmaceuticalreview
June 04, 2021
VAXELIS™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine), developed as part of a U.S.-based partnership between Merck and Sanofi Pasteur is now available in the ...
Sanofi halts venglustat clinical programme in ADPKD pharmatimes
June 02, 2021
French pharma company Sanofi has announced that it has halted the clinical programme of venglustat in autosomal dominant polycystic kidney disease (ADPKD).
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate worldpharmanews
May 28, 2021
Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate.
GSK, Sanofi launch late-stage COVID-19 vaccine study pharmatimes
May 27, 2021
GlaxoSmithKline (GSK) and Sanofi have begun enrolling participants into a Phase III clinical study of their adjuvanted recombinant-protein COVID-19 vaccine candidate.
Sanofi to provide fill and finish manufacturing support for Moderna vaccine cphi-online
May 24, 2021
French company is now providing manufacturing capacity to support three different COVID-19 vaccines
Sanofi’s Dupixent 'rapidly' improves lung function in children pharmatimes
May 18, 2021
Sanofi’s Dupixent significantly reduced severe asthma attacks and rapidly improved lung function in children aged six to 11 years old with uncontrolled moderate-to-severe asthma, according to detailed results from a Phase III trial.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page